Company Website

Contact Information:

Jamie Can
jamie.can@us.sumitomo-pharma.com
832-428-9097

Virtual Exhibit Hall Home

Watch our Video

INNOVATIONS TODAY, HEALTHIER TOMORROWS
Our Mission is "To contribute broadly to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By channeling efforts into the research and development of new drugs, Sumitomo Pharma aims to realize this Mission and provide innovative and useful pharmaceuticals and healthcare solutions to people in Japan and around the world.
Additional Information:
ORGOVYX: a once-daily pill to treat advanced prostate cancer*

ORGOVYX is the only oral androgen deprivation therapy (ADT) and was shown to lower testosterone and PSA levels† in adults with advanced prostate cancer.

*Take 3 pills on first day of treatment. Every day after, take 1 pill daily at about the same time each day.

†Even though it wasn’t the main focus of the clinical trials, prostate-specific antigen (PSA) levels were monitored. Because the clinical trial included many different types of patients, the results of PSA monitoring should be interpreted with caution. No evidence has shown that the speed of PSA decline is related to a clinical benefit.

ORGOVYX was studied in a clinical trial in more than 900 men with advanced prostate cancer. Men in the trial were treated for 48 weeks and either took the pill ORGOVYX or received leuprolide acetate injections.

The purpose of the trial was to measure how well ORGOVYX lowered testosterone to the treatment goal of below 50 ng/dL (nanograms per deciliter) from day 29 through week 48.

While it wasn't the main focus of the trial, the trial also monitored how much ORGOVYX was able to lower prostate-specific antigen (PSA) levels.‡

‡Because the clinical trial included many different types of patients, the results of PSA monitoring should be interpreted with caution. No evidence has shown that the speed of PSA decline is related to a clinical

ORGOVYX PI_1.pdf